

# Interface and Formulary Update - Issue 37

## July 2025

### Key messages from July 2025 TAG meeting - (ratified by Medicines Optimisation Programme Board)

#### **Commissioning Review – Guideline for the management of Vitamin B12 (Cobalamin) deficiency in over 16s and patient information leaflet Vitamin B12 Deficiency**

- Guidance document and patient information leaflet [published here](#)
- Project for future Prescribing Quality Scheme
- Vitamins and minerals commissioned to treat a diagnosed deficiency
- Once the deficiency has been corrected, patients are expected to purchase OTC products

#### **Commissioning Review - Antipsychotics – confirmation of traffic light classifications**

- Antipsychotics with existing **ADVICE** classification will be amended to **AMBER INITIATE**
- Specialist will initiate medication and provide the first month (three months in certain cases) before transferring prescribing to primary care
- New classification clarifies the wording previously used and removes ambiguity for prescribers

#### **Guidance Review - Pericyazine deprescribing guidance, letter and audit template**

- **Key message** - Only for deprescribing of pericyazine that has been initiated by a clinician in primary care. Do not stop or switch pericyazine prescriptions for schizophrenia or psychotic disorders. Refer these patients to NSFT for review
- Documents [published here](#)

#### **Guidance Review - Sublingual Immunotherapy (SLIT) - Acarizax to reduce allergy symptoms caused by a specific allergen**

- Prescribing Guidance document [published here](#)

#### **Guidance Review - Prescribing Guidance – Trurapi**

- Trurapi® (biosimilar insulin aspart) is the preferred first-line choice when prescribing insulin aspart
- All new patients requiring insulin aspart should be initiated on Trurapi® if appropriate.
- Switches from NovoRapid® to Trurapi® should be undertaken in primary and secondary care
- Guidance document [published here](#)

#### **Guidance Review - Structured Medication Review Toolkit**

- Bringing all resources into one document
- To support Prescribing Quality Scheme
- Toolkit published [here](#)

#### **Formulary Review - Luja™ with Micro-hole Zone Technology (MHZT) device urinary retention and/or post void residual volume due to bladder dysfunction from any aetiology**

- **BLACK – not commissioned. Not for prescribing in primary or secondary care**

### Shared Care Updates

#### **Use of Donepezil, Galantamine, Rivastigmine and Memantine in the treatment of Dementia**

- Move to **Amber Advice** with Prescribing Guidance document – [published here](#)

#### **Cenobamate for focal onset seizures in epilepsy as per TA753**

- Move from **SCA Level 0** to **Amber Initiate** with Prescribing Guidance document – [published here](#)

#### **Sacubitril Valsartan for treating symptomatic chronic heart failure with reduced ejection fraction**

- Currently under review. Updates to follow. Existing SCA [published here](#)

## Formulary and Guidance Updates

### Guidance Updates

- [Prescribing Guidance](#) – **Relugolix Estradiol Norethisterone (Ryeqo®▼)** for uterine fibroids
- [Respiratory documents](#)
  - [Best Value Inhalers](#)
  - [Inhalers licensed for Asthma](#)
  - [Inhalers licensed for COPD](#)
- [Dietetic updates](#)
  - Multivitamin and Mineral Supplementation and monitoring following Bariatric Surgery
  - Patient Leaflet - planning for privately funded bariatric (weight loss) surgery in the UK or abroad.
  - Patient Leaflet – Over the Counter Multivitamins and Minerals Post NHS Bariatric Surgery
  - How to lose weight in a healthy way
  - Home Enteral Feeds on Prescription

### Formulary updates

- **Vapro** No Touch Catheters – **BLACK**
- **CeraPlus** ostomy skin barrier – **BLACK**
- [Chapter 4](#) Central Nervous System is now live on Netformulary
- **Riluzole orodispersible tablets** – best-value switch from standard tablets

## Traffic Light Additions / Updates (to be read in conjunction with [TAG Agreement document](#))

<b>HOSPITAL / SPECIALIST ONLY</b>	<a href="#">TA1066 – June 2025</a> <b>Somapacitan (Sogroya®)</b> growth hormone deficiency people 3 to 17
	<a href="#">TA1071 – June 2025</a> <b>Atezolizumab (Tecentriq®)</b> adjuvant treatment of resected non-small-cell lung cancer
	<a href="#">TA1073 – June 2025</a> <b>Marstacimab (Hympavzi®)</b> severe haemophilia A or B in people 12 years and over without anti-factor antibodies
	<a href="#">TA1080 – July 2025</a> - <b>Mirikizumab (Omvoh®)</b> moderate to severe Crohn's disease
	<a href="#">TA1081 – July 2025</a> - <b>Zanubrutinib (Brukinsa®)</b> relapsed or refractory mantle cell lymphoma
<b>GREEN</b>	<a href="#">TA1075 – July 2025</a> - <b>Dapagliflozin (Forxiga®)</b> chronic kidney disease
<b>NICE-APPROVED</b>	<a href="#">TA1067 – June 2025</a> <b>Linzagolix (Yselty®)</b> symptoms of endometriosis
	<a href="#">TA1070 – June 2025</a> <b>Spesolimab (Spevigo®)</b> generalised pustular psoriasis flares
	<a href="#">TA1074 – June 2025</a> <b>Sparsentan (Filspari®)</b> primary IgA nephropathy
<b>BLACK</b>	<a href="#">TA1069 – June 2025</a> <b>Efgartigimod (Vyvgart®)</b> antibody-positive generalised myasthenia gravis
	<a href="#">TA1068 – June 2025</a> <b>Tislelizumab</b> unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy
	<a href="#">TA1072 – June 2025</a> <b>Tislelizumab</b> advanced non-small-cell lung cancer after platinum-based chemotherapy
	<a href="#">TA1078 – June 2025</a> <b>Fosdenopterin</b> molybdenum cofactor deficiency type A

## Useful Information

<b>Next TAG meeting</b>	<b>Wednesday 3<sup>rd</sup> September 2025</b>
<b>Deadline for agenda items</b>	<b>Tuesday 26<sup>th</sup> August 2025</b>
<b>Netformulary</b>	<a href="#">Norfolk and Waveney Formulary (norfolkandwaveneyformulary.nhs.uk)</a>
<b>Knowledge NoW – MO Team pages</b>	<a href="#">Prescribing, Pharmacy and Medicines Optimisation - Knowledge NoW (nwknowledgenow.nhs.uk)</a>
<b>TAG Guidance</b>	<a href="#">Therapeutic Advisory Group (TAG) and Commissioning - Knowledge NoW (nwknowledgenow.nhs.uk)</a>
<b>Shared Care Agreements</b>	<a href="#">Shared Care Agreements - Knowledge NoW (nwknowledgenow.nhs.uk)</a>
<b>Pathways and Prescribing Guidance</b>	<a href="#">Pathways and Prescribing Guidance - Knowledge NoW (nwknowledgenow.nhs.uk)</a>
<b>Practice Support</b>	<a href="#">Practice Support - Knowledge NoW (nwknowledgenow.nhs.uk)</a>
<b>Useful Links</b>	<a href="#">Useful Links - Knowledge NoW (nwknowledgenow.nhs.uk)</a>

- **Please remember to check both [KNoW](#) and [Netformulary](#) for regular formulary updates**
- If you have any interface or formulary queries, please send to the inbox - [nwicb.medsqueries@nhs.net](mailto:nwicb.medsqueries@nhs.net)